welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)
study id #: NCT03769116
condition: Muscular Dystrophy, Duchenne
The purpose of this study is to evaluate the safety and efficacy of exogenous gene transfer in DMD patients by measuring biological and clinical endpoints in two parts: a 48-week randomized, double-blinded, placebo-controlled period (Part 1), and a 96-week, double-blinded extension period (Part 2).
intervention: SRP-9001, Placebo
mechanism of action: Gene therapy to introduce a version of dystrophin
last updated: January 21, 2019
start date: December 22, 2018
estimated completion: December 31, 2021
phase of development: Phase 2
size / enrollment: 24
- Incidence of Serious Adverse Events (SAEs) [ Time Frame: Up to 144 weeks ]
- Incidence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 144 weeks ]
- Incidence of Adverse Events of Special Interest (AESIs) [ Time Frame: Up to 144 weeks ]
- Change from Baseline in Quantity of Microdystrophin Protein Expression [ Time Frame: Baseline, Week 12 ]
• Established clinical diagnosis of DMD and documented dystrophin gene mutation of DMD phenotype.
• Indication of symptomatic muscular dystrophy by protocol-specified criteria.
• Ability to cooperate with motor assessment testing.
• Stable dose equivalent of oral corticosteroids for at least 12 weeks.
• Impaired cardiovascular function on ECHO.
• Prior or ongoing medical condition on physical examination, ECG, or laboratory findings that could adversely affect subject safety, compromise completion of follow-up, or impair assessment of study results.
• Exposure to another investigational drug or exon skipping medication within months.
• Exposure to an investigational or commercial gene therapy product.
• Abnormal liver or renal function by protocol-specified criteria
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
NCATS, FDA Co-Host Workshop on Gene Therapy for Rare Diseases“We are now at the point of translatin...
The Gene-Edited Babies And CRISPR-Cas9 Controversy, ExplainedOutrage continues to grow over the news ...
New lab technology could reveal treatments for muscle-wasting diseaseResearchers from Queen Mary University o...
Open Label Study of GSK2402968 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to explore ...
Preliminary Data and Intention to Dose Escalate in IGNITE DMDToday we announced our intention to move...
U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editingA U.S. appeals court on Monday allowed a...